Edition:
United States

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

3.98USD
14 Dec 2018
Change (% chg)

$-0.02 (-0.50%)
Prev Close
$4.00
Open
$3.98
Day's High
$4.08
Day's Low
$3.96
Volume
100,960
Avg. Vol
169,933
52-wk High
$7.55
52-wk Low
$3.61

Latest Key Developments (Source: Significant Developments)

Foamix Announces Positive Topline Results From Phase 3 FMX103 Topical Minocycline Foam
Wednesday, 7 Nov 2018 07:44am EST 

Nov 7 (Reuters) - Foamix Pharmaceuticals Ltd ::FOAMIX PHARMACEUTICALS SAYS STUDIES FX2016-11 & FX2016-12 MET BOTH CO-PRIMARY ENDPOINTS.FOAMIX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 PROGRAM EVALUATING FMX103 TOPICAL MINOCYCLINE FOAM FOR MODERATE-TO-SEVERE PAPULOPUSTULAR ROSACEA.FOAMIX PHARMACEUTICALS SAYS FMX103 DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT VERSUS VEHICLE IN BOTH CO-PRIMARY EFFICACY ENDPOINTS.FOAMIX PHARMACEUTICALS SAYS SAFETY PROFILE OF FMX103 WAS FOUND TO BE FAVORABLE; FMX103 APPEARED TO BE GENERALLY SAFE & WELL-TOLERATED.FOAMIX PHARMACEUTICALS SAYS DATA FROM STUDY FX2016-13 EVALUATING LONG-TERM SAFETY OF FMX103 ARE EXPECTED TO BE REPORTED IN H1 2019.FOAMIX PHARMACEUTICALS SAYS GOAL IS TO FILE NDA FOR FMX103 IN 2019.  Full Article

Foamix Announces Additional Positive Topline Results From Third Phase 3 Trial
Monday, 1 Oct 2018 08:42am EDT 

Oct 1 (Reuters) - Foamix Pharmaceuticals Ltd ::FOAMIX ANNOUNCES ADDITIONAL POSITIVE TOPLINE RESULTS FROM THIRD PHASE 3 TRIAL (STUDY FX2017-22) EVALUATING FMX101 TOPICAL MINOCYCLINE FOAM FOR MODERATE-TO-SEVERE ACNE.FOAMIX PHARMACEUTICALS LTD - STATISTICALLY SIGNIFICANT IMPROVEMENT DEMONSTRATED IN REDUCTION OF NON-INFLAMMATORY LESIONS.FOAMIX PHARMACEUTICALS - SAFETY PROFILE OF FMX101 WAS CONSISTENT WITH THAT DETERMINED FROM TWO PRIOR PHASE 3 STUDIES.FOAMIX PHARMACEUTICALS LTD - DERMAL TOLERABILITY SCORES CONSISTENT WITH PREVIOUS PHASE 3 STUDIES.FOAMIX PHARMA-RESULTS FROM BOTH CO-PRIMARY ENDPOINTS DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT RESULTS FOR FMX101 VERSUS VEHICLE, WITH P-VALUES <0.0001.  Full Article

Foamix Pharmaceuticals Q2 Loss Per Share $0.46
Wednesday, 8 Aug 2018 04:01pm EDT 

Foamix Pharmaceuticals Ltd ::FOAMIX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.46.Q2 EARNINGS PER SHARE VIEW $-0.56 -- THOMSON REUTERS I/B/E/S.AT JUNE 30, 2018, COMPANY HAD $56.4 MILLION IN CASH AND INVESTMENTS COMPARED TO $76.4 MILLION AT DECEMBER 31, 2017.REVENUES FOR Q2 2018 WERE $964,000 AN INCREASE OF 20.8% Q2 OF 2017.  Full Article

Foamix's treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.